Continuous Glucose Monitoring Following Hospital Discharge
NCT ID: NCT05360056
Last Updated: 2025-12-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
108 participants
INTERVENTIONAL
2022-04-26
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexcom G6 Intervention Study
NCT03877068
Dexcom G6 Observational Study
NCT03832907
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
NCT05548205
Dexcom G6 for Total Pancreatectomy With Islet Autotransplantation (TPIAT) Patients
NCT05607576
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
NCT06852950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexcom CGM
DexCom G6
Wearable continuous glucose monitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DexCom G6
Wearable continuous glucose monitor
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Basal insulin use \>10 units per day
* Hemoglobin A1c \>8.0%
* Smartphone compatible with Clarity App
* Age ≥18 years
Exclusion Criteria
* Inability to consent
* Pregnancy
* Prisoners
* Discharge to skilled nursing facility
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DexCom, Inc.
INDUSTRY
Kathleen Dungan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kathleen Dungan
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen Dungan, MD
Role: PRINCIPAL_INVESTIGATOR
OSU Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University Medical Center - Outpatient Care East
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021H0426
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.